placeholder
Importance
55
Trust
71
Urgency
30
COMMERCIAL
BMO Lifts Novo Nordisk Target As Wegovy Pill Gains Traction - Finimize
Investment bank BMO raised its price target for Novo Nordisk after the pill version of Wegovy (semaglutide) showed growing customer interest. The bank's forecast suggests the oral drug could help boost the company's sales and stock value.
Analysis
A pill form of Wegovy is easier to take than shots. If sales grow, Novo could win back ground it lost to Lilly in the weight-loss drug race.
- BMO raised its price target on Novo Nordisk
- The bank cited growing interest in the Wegovy pill
- Wegovy pill is the oral version of semaglutide
Semaglutide News1mo
Read